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Oral absorption of compounds depends on many physiological, physiochemical and formulation factors.
Two important properties that govern oral absorption are in vitro permeability and solubility, which are
commonly used as indicators of human intestinal absorption. Despite this, the nature and exact char-
acteristics of the relationship between these parameters are not well understood. In this study a large
dataset of human intestinal absorption was collated along with in vitro permeability, aqueous solubility,
melting point, and maximum dose for the same compounds. The dataset allowed a permeability
threshold to be established objectively to predict high or low intestinal absorption. Using this perme-
ability threshold, classification decision trees incorporating a solubility-related parameter such as
experimental or predicted solubility, or the melting point based absorption potential (MPbAP), along
with structural molecular descriptors were developed and validated to predict oral absorption class. The
decision trees were able to determine the individual roles of permeability and solubility in oral ab-
sorption process. Poorly permeable compounds with high solubility show low intestinal absorption,
whereas poorly water soluble compounds with high or low permeability may have high intestinal ab-
sorption provided that they have certain molecular characteristics such as a small polar surface or
specific topology.
© 2015 Elsevier Masson SAS. All rights reserved.1. Introduction
The assessment of pharmacokinetic properties, especially ab-
sorption, is now well established in early drug discovery. The need
to determine absorption of new chemical entities is essential for
successful orally administered compounds, as well as efficacy,
toxicity and other ADME (absorption, distribution, metabolism,
excretion) properties [1]. The prediction of oral absorption can be
carried out with experimental assays and/or the use of in silico
models. These experimental and computer models can be used as
an indication of intestinal absorption in humans, which is carriedestinal absorption; BCS, Bio-
ation and regression trees;
false negative; FP, false posi-
arby Canine Kidney; MPbAP,
antitative StructureeActivity
egative; TP, true positive.
acy, Universities of Kent and
urian).
served.out later on in drug development. By testing drug compounds using
these models, compounds with undesirable properties can be
removed earlier, therefore improving cost effectiveness [2,3].
Intestinal absorption depends on many physiological, physi-
ochemical and formulation factors. Two important properties that
govern oral absorption are permeability and solubility as utilised by
the Biopharmaceutics Classification System (BCS) [4]. For a drug to
be absorbed it must firstly dissolve in the gastrointestinal fluid in
order to then permeate the intestinal membrane. The relationship
between these properties is closely, usually inversely, related [5,6].
As an increasing number of new chemical entities (NCE) have high
lipophilicity and low solubility, predicting absorption of NCEs is
problematic. Inadequate aqueous solubility can lead to poor, erratic,
variable absorption, so it is important to consider the effects of
solubility for the prediction of intestinal absorption [7].
The importance of solubility on oral absorption is highlighted in
the literature, but there are few studies that incorporate both
experimental solubility and permeability values within a model, in
order to see the effect these two properties have on oral absorption
[8,9]. Early oral absorption models are too small to effectively
represent all the different biological processes of absorption and
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studies have removed compounds with solubility issues when
modelling oral absorption [12,13], which is not ideal due to the
increasing number of poorly soluble drugs being developed. Zhao
and co-workers demonstrated that predicting BCS Class II com-
pounds (low solubility and high permeability) resulted in an
overestimation of fraction absorbed by their model [12]. Solubility
itself is a complex parameter and in turn dependent on numerous
factors, therefore it is important to investigate what multiple ele-
ments such as those calculated from the molecular structure may
improve understanding of this property in relation to absorption.
Molecular descriptors that describe the process of solubilisation
of the drug such as crystal lattice energy, solvent cavity formation
energy and solvation energy are utilised in the prediction of solu-
bility [14,15]. The general solubility equation (GSE) is a simple
method that predicts aqueous solubility using only two parameters,
log P and melting point [16]. Other methods may employ more
specific molecular descriptors to improve the prediction accuracy
[17,18]. GSE and its variants have been used for the estimation of
oral absorption-related parameters termed absorption potential
[19,20]. Recently a melting point based absorption potential
(MPbAP) has been proposed which is derived from the GSE and
includes maximum dose, to give an indication of oral absorption. In
general, it was found that the lower the melting point the higher
the tendency the compound had to be highly-absorbed and vice
versa, and it was also found that for higher melting points ab-
sorption was limited by dose [21].
Permeability in drug discovery is routinely measured using
in vitro cell based assays to give an indication of permeability of
drug compounds in the intestine, blood brain barrier, nasal cavity
and skin [22]. Apparent permeability (Papp) is the rate of perme-
ation across cell monolayers and is usually measured in cm/s1. The
ideal permeability model for the small intestine mimics the phys-
ical and biochemical processes of intestinal absorption [1]. There
are many different cell lines that can be used to measure perme-
ability. Human colon adenocarcinoma (Caco-2) is a commonly used
cell line [23e25], which displays biological and characteristic
properties of the enterocytes of the small intestine such as the
brush border and tight junctions [1,25e27]. These cells can express
a variety of transporters and metabolic enzymes, allowing other
transport and metabolism mechanisms to be investigated [28].
Drawbacks of this particular cell line are inter-laboratory differ-
ences, variable transporter expression, long culture time, tighter
junctions compared with in vivo situation and lack of mucus
secreting goblet cells [1,29,30]. Some of these problems have been
resolved by other cell lines such as 2/4/A1, a rat intestinal epithelial
cell line, which has leakier tight junctions [31,32]; also, the cell line
HT29-MTX is a co-culture of Caco-2 cells with mucus secreting
goblet cells to study the effects of mucus on absorption [33].
Another cell line that has been gaining popularity is MDCK II
(MadineDarby Canine Kidney strain II) cells, due to shorter culture
time (of 3e5 days), leakier tight junctions and low expression of
transporters compared with Caco-2, making it an ideal cell line for
passive permeability assessment even with species and tissue dif-
ferences [22,34e36]. There are many similarities and differences
between Caco-2 and MDCK cell lines. Despite this there is a linear
relationship between the two shown using small compound sets
[22,34,35].
The relationship between permeability and fraction absorption
in humans can be determined numerically or categorically. From a
classification perspective a permeability threshold indicates high or
low intestinal absorption (absorption class). The permeability
thresholds defined in the literature vary greatly and the majority of
studies appear to set the permeability threshold subjectively from a
visual inspection of the graphical fit, rather than using an objectivemethod [13,37e40]. For example, Artusson et al. [37], using a
dataset of 20 compounds, defined that a compound would have
complete absorption if it had a permeability >1  106 cm/s. More
recent studies have indicated higher permeability thresholds than
1  106 to define a high absorption compound [8,38,41]. In a
recent investigation, Varma et al. [36], used Receiver Operating
Characteristic (ROC) analysis to objectively define the best perme-
ability threshold for fraction absorbed based on a dataset of 82
compounds with permeability measured in a low transporter
expression MDCK II cell line. The threshold defined was
>5  106 cm/s for 80% or 90% fraction absorbed. Additionally,
the FDA has recommended a set of high and low permeability
standards with known fraction absorbed [42]. These standard
compounds can be measured alongside NCEs which are then
considered as highly or poorly permeable, depending on whether
the permeability is greater or lower than the standards; this can
then be related to fraction absorbed based on these FDA standards.
Potential problems with this are the choice of standard. For
example, the high permeability standards propranolol, verapamil
and metoprolol have differences in their permeability which could
result in potential incorrect prediction depending which standard
is used when testing alongside NCEs.
In order to see the effects of solubility and permeability on
fraction absorbed, a large dataset is needed. Therefore, the first aim
of this work was to expand the permeability dataset by combining
data from Caco-2 and MDCK cell lines. By studying the relationship
and the effect of different absorption mechanisms between the two
cell lines and from the differences already known between the two
cell lines, the justification of combining the datasets can be shown.
Secondly, the determination of a permeability threshold to predict
fraction absorbed class using an objective decision tree method is
tested on an external validation set of the permeability dataset
collected. Using this permeability threshold, decision trees using
experimental and predicted solubility and related properties such
as dose number and melting point were included along with
structural molecular descriptors to build classification models to
predict fraction absorbed class. Therefore, the QSAR endpoint is the
categorical variable indicating the ‘high’ or ‘low’ fraction absorbed
class. Based on this work, one can obtain an increased under-
standing around the relationship between two popular cell based
assays and how they can be used to predict absorption class using
an objective permeability threshold. In addition, the effect of sol-
ubility and related properties on the prediction of fraction absorbed
models is explored.
2. Methods and materials
2.1. Datasets
With an extensive search in the literature, multiple datasets
were collated consisting of data for human intestinal absorption,
transport route, permeability, solubility, dose number, aqueous
solubility and melting point. For each compound the name, prop-
erty value, CAS number, references and additional comments from
the authors relating to the data is included and can be found in the
Supporting Information I. Whenever possible, the original litera-
turewas consulted to evaluate data quality. In some cases data from
secondary sources was included when original literature could not
be located.
2.1.1. Human intestinal absorption
Intestinal absorption can be assessed and calculated from
different types of data such as bioavailability, and urinary and faecal
excretion mass balance studies. We used the same principles to
calculate and evaluate the reliability of fraction absorbed value as
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initially obtained from the published datasets of Hou et al. [13] and
Varma et al. [43]; this data was scrutinised by checking the original
publications. An exhaustive search of the literature was then car-
ried out and additional compounds were also added from the drug
information obtained from the FDA Drugs@FDA database (accessed
from June 2012 to May 2013) [44]. Where there was no numerical
value defined in the literature, categorical values for fraction
absorbed were also included for this dataset. At the end, the dataset
consisted of 913 numerical and 19 categorical fraction absorption
values creating a final dataset of 932 compounds.
2.1.2. Permeability
Apparent permeability (Papp) data measured in cm/s1 was
collected for compounds with known fraction absorption. The
dataset contains apparent permeability data for the two different
cell lines Caco-2 and MDCK obtained from the literature. The
dataset contains 386 Caco-2 and 246MDCK Papp values for drug and
drug-like compounds. For 185 compounds the permeability was
found for both cell lines, and this dataset was used to investigate
the relationship between the two cell lines. Where there were
multiple permeability values for a single compound these results
were averaged unless they were very different, in which case
comparison of MDCK and Caco-2 permeability was carried out (if
available) or careful examination of the experimental conditions of
the specific value was performed in order to justify inclusion.
For Caco-2 permeability, the published dataset by Pham-The
et al. [45] was used as the starting point from which an exhaus-
tive literature search was carried out. For MDCK permeability,
permeability data from two studies by Varma and co-workers
[36,46] were used as a starting point. As there are different
strains of this cell line, it was important to reference what strain (if
known)was used in the study. In addition, it was decided not to just
isolate data collection on one strain, but make a note which would
aid in interpretation at a later stage. The main two types of MDCK
strains collected were MDCK II and MDCK-MDR1. A preliminary
statistical paired t test of these two main strains showed no sig-
nificant difference between these two strains in this dataset
(p > 0.05), therefore all the data for MDCK was used together for
comparison with Caco-2.
2.1.3. Identification of absorption mechanisms
The knowledge about absorption mechanism will help with
interpretation of models and give us a better understanding of the
influence of transporter systems on absorption as this is increas-
ingly important in the prediction of drug absorption. For each
compound the absorption route was assessed using literature data,
review articles and transporter databases. It was recorded if com-
pounds underwent any absorption mechanism other than passive
transcellular route. This included carrier mediated systems, such as
efflux and influx transporters, and paracellular absorption. A total
of 201 (out of 932) were identified to be absorbed via routes other
than passive transcellular. It must be noted that, firstly, if no in-
formation or evidence was found to suggest alternative absorption
mechanisms, this does not necessarily mean it is not a substrate of a
transporter or transported via the paracellular route; it may not
have been tested and/or results have not been published in the
literature. Therefore, in the future we anticipate that this number
could increase further when more research is carried out. Secondly,
although a compound is identified as a substrate for a carrier
mediated system, this does not mean that the transport system is
the dominating process [47].
2.1.4. Aqueous solubility
Aqueous solubility for 483 compounds in mg/mL was obtainedprimarily from the AQUASOL dATAbASE (6th Edition) and SRC
(PHYSPROP) databases (http://esc.srcinc.com/fatepointer/search.
asp) and the literature. Solubility was converted to log molar
units (M) and log mg/mL units in this work. For the AQUASOL data,
those values that had the highest evaluation codes as defined by the
database were selected, and those compounds with more than one
value were averaged.
In addition to these values, predicted solubility values were also
utilised and compared with experimental in the modelling section
of this work. Solubility was calculated by the revised general sol-
ubility equation (GSE) using experimental melting point and
calculated log P [16]. (Equation (1) below).
Log SolðGSEÞ ¼ 0:5 0:01ðMP  25Þ  log P (1)
2.1.5. Dose number
Dose number is a dimensionless number used to determine high
or low solubility in the Biopharmaceutical Classification System
(BCS) [4]. It is calculated using the solubility and maximum
strength dose (Equation (2)).
Do ¼ ðMo=VoÞ=S (2)
where Do is dose number, Mo is the highest dose strength, Vo is
250 ml and S is the aqueous solubility (mg/ml). The maximum
strength dose was obtained for the compounds in this dataset from
the British National Formulary (2012) [48], FDA electronic orange
book 2012 (accessed December 2012eJanuary 2013) and Martin-
dale (2009) [49]. Where there were still missing values, an exten-
sive literature search was carried out and the values presented are
the authors' best recommendation based on an evaluation of the
literature data. Where doses were based on bodyweight, a body
weight of 70 kg was used to calculate the maximum dose for
human.
2.1.6. Melting point
Experimental melting point (in C) was obtained from the
AQUASOL dATAbASE, SRC (Physprop), the Hazardous substances
data bank (HSDB) (http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?
HSDB) and the literature. The average was taken if a melting
point range was stated.
2.1.7. Melting point based absorption potential
The melting point based absorption potential (MPbAP) was
derived from the GSE but utilising maximum dose as well as
melting point [21]. As shown by Equation (3) below.
MPbAP ¼ 0:5 0:01ðMP  25Þ  logð4*Max DoseÞ (3)
2.2. Calculated molecular descriptors
Calculated molecular descriptors were calculated from struc-
tures using the software packages TSAR 3D v3.3 (Accelrys Inc.),
MDL QSAR (Accelrys Inc.), MOE v2010.10 (Chemical Computing
Group Inc.) and Advanced Chemistry Development ACD Labora-
tories/Log D Suite v12. Including the seven descriptors of perme-
ability, solubility and related parameters, a total of 220 molecular
descriptors were utilised for analysis.
2.3. Training and validation sets
Using the combined permeability data from the two cell lines
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MDCK and Caco-2 permeability data that differed bymore than one
log unit and one compound that did not have a numerical value for
HIA were removed (14 compounds in total). This resulted in a
dataset of 433 compounds. The 433 compounds were split into a
training set and a validation set. To ensure a similar distribution of
fraction absorbed in these two sets, compounds were sorted ac-
cording to ascending %HIA and then log P values. From each group
of six consecutive compounds, five were assigned to the training
set, and one compound was allocated to the validation set
randomly. The initial training set consisted of 356 compounds and
the validation set consisted of 78 compounds.
For models used to determine the influence of solubility and
related parameters, compounds that had missing values for solu-
bility, melting point and dose number were removed from the
initial training and validation sets. The final compound numbers for
decision tree analysis are shown in Table 1.2.4. Classification and regression trees (CARTs)
STATISTICA v11 (StatSoft Ltd.) software was used for perme-
ability threshold determination and classification of compounds
using CART analysis. CARTs (called C&RT in the STATISTICA soft-
ware) use decision trees to solve regression and classification
problems developed by Breiman et al. [50]. Hence, in this work the
QSAR models are represented as decision trees (a type of graph).
According to the observed %HIA values in the data set, compounds
were placed into either the “high” class if %HIA was equal to or
greater than a specified HIA cut-off (e.g. 50%) or the “low” class if %
HIA was less than this specified %HIA cutoff. In this work binary
classification of (low or high HIA) was carried out using calculated
molecular descriptors from the chemical structure, permeability
and solubility related parameters. The QSAR models (in the form of
decision trees) used in this work were validated by measuring the
predictive accuracy of model predictions (prediction of “High” or
“Low” oral absorption class) for the compounds in the validation
set, as described earlier (section 2.3 e training and validation sets).
Preliminary results indicated that permeability and not solubi-
lity was the dominant property selected statistically by CART.
Therefore in order to gauge the relative importance of these two
parameters, the decision trees were built in two phases. The first
phase forced CART to select a suitable permeability threshold for
different HIA class definitions. The second phase involved forcing
CART to choose thresholds for solubility and related parameters for
the second split of the decision tree. After this, CARTwas allowed to
build the remainder of the tree automatically using structural
molecular descriptors. These trees were compared with a CART tree
developed using the parameters selected automatically by the tree
from permeability or solubility parameters or the molecular de-
scriptors provided.Table 1
Compound numbers used in the training and validation sets for decision tree
analysis.
Property Total number of compounds Training set Validation set
n n
Permeability 433 356 77
Solubility 296 242 54
GSE solubility 315 262 53
Dose number 292 239 53
Melting point 315 262 53
MPbAP 308 257 512.5. Permeability threshold determination using CART
The permeability threshold is the numerical value chosen by
CART that best predicts HIA class. In this work several different
analyses were performed where high absorption compounds were
defined as those having HIA values of above 30, 50, 70, 80 or 90%.
Using the training set of 356 compounds, HIA class was used as the
dependent variable and permeability as the independent variable.
The CART analysis was restricted to only one split to give the
permeability threshold. This threshold was tested using a valida-
tion set of 78 compounds. Due to the class imbalance, where there
are many more highly-absorbed than poorly-absorbed compounds,
higher misclassification costs were applied to false positives to
overcome this bias. Based on previous works the use of misclassi-
fication costs has shown improved model accuracy [51]. The
misclassification cost values applied depended on the class distri-
bution of the dataset. For instance, when the “high absorption”
class is defined as having %HIA30%, the cost of a false positive was
considered five times the cost of a false negative due to roughly five
times more highly absorbed compounds in the data set. Misclas-
sification costs of 5, 4, 3, 2.5 and 2 were applied to false positives in
the analyses where the high HIA class had been defined as those
compounds having %HIA values equal or above 30, 50, 70, 80 and
90%, respectively.
2.6. Permeability and solubility related model analysis for oral
absorption class determination
In this section, models were built using HIA class as the
dependent variable where high absorption was defined as HIA
80% and molecular descriptors were utilised as the independent
variables for model building. The HIA class definition of 80% was
selected based on preliminary work, where when using lower HIA
class definition such as 30e70% due to the lower number of poorly
absorbed compounds only poor models could be achieved. Using a
higher threshold of 90% resulted in poorer overall accuracy (based
on preliminary analysis), and this threshold is too high to predict
oral absorption class effectively with a high number of false
negatives.
In this work permeability was set as the first split variable and
two alternative approacheswere used to choose the remaining split
variables. In the first one, the CART tree was allowed to grow
automatically. In the second one, each of the solubility and related
parameters (dose number and melting point) were manually cho-
sen as then second split variable (note that CART still chooses the
cut-off point automatically) and then the tree was allowed to grow
automatically. Stopping factors were used to prevent overfitting of
the CART trees and was the minimum number of compounds for
splitting. This was set at 11 for the permeability only CART trees and
eight for permeability and solubility trees.
2.7. Statistical significance of the models
To determine the relationship between Caco-2 and MDCK
permeability, MINITAB Statistical Software (version 16.1.1.0) and
Prism (GraphPad Software, Inc) v.5.02 were used to carry out linear
regression, identify outliers and perform statistical significance
testing between the different absorption mechanisms. For linear
regression the parameter reported to assess the fit of the two var-
iables was the squared correlation coefficient, r2 forced through the
origin. For correlation analysis the Pearson's correlation coefficient
and the Spearman's ranking correlation coefficient (rs) were
calculated. It must be emphasised here that r2 based on the
regression line forced through the origin is not comparable to r2
values where the regression line is not forced through the origin
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lines and comparison of the regression lines for different absorp-
tion mechanisms (using the intercept and the slope values) was
depicted by p values. P values <0.05 indicated significance.
The predictive performance of the classification models built
using CART in this work was measured using sensitivity (SE),
specificity (SP) and SP  SE. Sensitivity is the ratio of correct clas-
sifications for the highly absorbed compound class (SE ¼ TP/
(TP þ FN)), where TP is the number of true positives and FN is the
number of false negatives. Specificity is the ratio of correct classi-
fications of poorly absorbed compounds (SP ¼ TN/(TN þ FP)),
where TN is the number of true negatives and FP is the number of
false positives. In this work overall accuracy is defined by specificity
multiplied by sensitivity (SP  SE). This measure represents the
overall predictive performance of both high and low class predic-
tion. In addition, this measure will not be overly influenced by the
classification accuracy of the majority high absorption class, and it
has been used in previous investigations [51,53].
3. Results and discussions
In this work in order to investigate the effects of permeability
and solubility a large dataset of human intestinal absorption was
gathered from the original literature and then for the same com-
pounds Caco-2 and MDCK permeabilities, solubility, melting point
and dose were gathered from the original literature. Table 2 shows
the collated data which is available in the supporting information I,
where n denotes the number of compounds for each property. This
data was used in order to develop models for predicting high/low
oral absorption and to explore suitability of different solubility and
permeability measures from different sources as descriptors of in-
testinal absorption.
In terms of permeability, we have gathered permeability
measured in both Caco-2 and MDCK cell lines. In vitro permeability
through different cell lines is commonly used as a high throughput
measure of effective intestinal absorption in early drug discovery.
Other cell lines such as MDCK, 2/4/A1 and HT29-MTX have also
been used to assess compound permeability. There have been a few
studies, which show the linear relationship between these cell
lines. For example, Braun et al. [22] studied the relationship be-
tween Caco-2 and MDCK cell lines and from 14 compounds ach-
ieved an r2 of 0.86. However, Avdeef et al. [35] achieved a r2 of 0.90
using a dataset of 79 compounds.
3.1. Comparison of Caco-2 and MDCK apparent permeability as
indicators of intestinal absorption
For 185 compounds, the in vitro apparent permeability from
both Caco-2 and MDCK cell lines was obtained from the literature.
By an exhaustive literature search transport routes were identified
for all these compounds. Plotting the permeability of these two cell
lines on a log scale a linear relationship is shown (Fig. 1) where the
transport routes have also been highlighted. Out of 185 compounds
in this figure, 96 compounds were found to be substrates of aTable 2
Data sets collated from the literature.
Property n





Melting point 609transporter system and 11 compounds have been suggested to be
absorbed to some extent via paracellular route.
It can be seen in the plot that Caco-2 and MDCK permeability of
majority of compounds regardless of their absorption routes
correlate well with each other. However, there are compounds that
deviate significantly from this line and removal of 9 outlier com-
pounds (compound names shown in Fig. 1) improves the correla-
tion significantly (Table 3). Details of the outlier compounds and a
description of reasons can be found in Supporting Information II. A
better linear relationship between the two cell lines is also achieved
when only compounds undergoing passive transcellular absorption
are plotted (Table 3). It may be noted in Table 3 that the correlation
between the cell lines is better after the removal of 9 outliers than
after the removal of all the compounds with a transporter effect. It
is also noteworthy that not all the outliers were substrates of a
transporter; examples are phenazopyridine and glipizide where no
transport system other than passive-transcellular has been identi-
fied. Both these drugs have poor solubilities (dissolution limiting
solubility) and classed in Class II of Biopharmaceutics classification
system (BCS) [54,55].
Similar conclusions can be made from the results of previous
studies where transporter mediated effects could not be identified
by correlating the permeability through different cell lines. Irvine
et al. [34] compared the apparently permeability of 55 compounds
using MDCK and Caco-2 cells. This study achieved an r2 of 0.79.
Irvine identified 12 compounds that were substrates for carrier
mediated systems. We crossed referenced the remaining com-
pounds used by Irvine with our database and identified an addi-
tional 18 compounds to be substrates for carrier mediated systems.
Therefore over half of this original dataset has now been found to
be affected by a carrier mediated route. The 12 compounds high-
lighted as undergoing carrier systems in most cases were within
the linear fit of Irvine's, with only a few exceptions. The explanation
by Irvine of why known P-gp substrates were not identified in
comparing the two cell lines is not suitable. For the P-gp substrates
highlighted in the work, it was stated the reason they could not be
identified was due to saturation of the transport mechanism in the
assay. Braun et al. [22] used the same compounds but at lower
concentrations, and they were still unable to identify known P-gp
substrates. It was concluded that using the relationship between
MDCK and Caco-2 could not identify P-gp substrates. From this
work the correlation between MDCK and Caco-2 permeability does
indicate the same result that compounds with carrier mediated
mechanisms do not deviate from the correlation between Caco-2
and MDCK permeabilities. This is despite the fact that the trans-
porters have different abundance levels in these two cell lines.
We have complied a table that compares the cells and small
intestine in terms of species origin, tightness of the cell junctions
and also the transporter and enzyme expressions (Table S1 in
Supporting Information III). One thing to note is the lack of infor-
mation/evidence in the literature for transporter and enzyme
expression especially for the specific strains of the MDCK cell line,
which is less well studied. For the small intestine the expression of
transporters and enzyme systems can vary from the three sections
of the small intestine, as compounds are not just absorbed from one
section, we tried to accommodate an overview of expression from
the human small intestine [56]. It can be seen from Table S1 that the
main differences between MDCK and Caco-2 cell lines in general
are that MDCK does not express some transporter types and that
MDCK has a lower abundance of some of the other transporters
compared to Caco-2 cell lines. However it must be noted that
expression of transporters or enzymes does not necessarily corre-
late with their functionality for affecting the absorption of the
compounds across different membrane/cell lines [57,58], and as it
was shown earlier, most substrates of different transporters do not
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Fig. 1. Linear relationship between Caco-2 and MDCK apparent permeability for 185 compounds.
Table 3
Statistical parameters for the linear relationship between MDCK and Caco-2
permeability measured using PRISM.
Datasets r2 (with intercept) r2 (non-intercept) Rp Rs
All compounds (185) 0.63 0.60 0.79 0.79
Passive transcellular (83) 0.71 0.69 0.84 0.74
Outliers removed (9 removed)
All compounds (176) 0.73 0.72 0.86 0.84
Passive transcellular (81) 0.75 0.75 0.87 0.76
Table 4
The different identified absorption mechanism of the 185 compounds.
Transport route Number of
compounds
Examples
Passive transcellular (A) 83 sumatriptan, valsartan
Passive paracellular (B) 6 lucifer yellow,
mannitol
Efflux (C) 62 vinblastine, saquinavir
Efflux and paracellular (D) 2 famotidine, cimetidine
Influx (E) 15 amoxicillin,
tolbutamide
Influx and paracellular (F) 2 soltalol, atenolol
Efflux and influx (G) 14 talinolol, acebutolol
Influx, efflux and paracellular
(H)
1 ranitidine
D. Newby et al. / European Journal of Medicinal Chemistry 90 (2015) 751e765756deviate from the correlation between Caco-2 and MDCK
permeabilities.
The different expression levels of metabolising enzymes in the
different cell lines could also potentially affect the permeability of
compounds. The expression and activity of CYP3A4 enzymes in
Caco-2 cells are either not present or very weak [30,59]. A recent
investigation has found no evidence of CYP3A4 expression inMDCK
II cells [60]. Unfortunately the lack of information regarding enzy-
matic activity in the cell lines makes it difficult to comprehensively
compare and contrast the suitability of these in vitro tools as in-
dicators of intestinal absorption.
Cell based assays, particularly Caco-2, have a reputation for
variability. The differences can arise from the experimental condi-
tions, which in turn can affect the monolayer, those that affect the
analysis of samples and also the physiochemical properties of the
compound [61]. A good example is solubility, which depending on
experimental conditions can cause variation particularly for com-
pounds with low solubility such as the outlier compounds phena-
zopyridine and glipizide [54,55] (Fig. 1).
The prime purpose of cell based assays such as Caco-2 and
MDCK is to study the rate of passive permeability rather than other
transport routes involving influx and efflux transporters. In this
dataset, out of the 185 compounds, 96 were identified as under-
going transport routes other than passive. In some cases, more than
one route was identified as being involved for the transport of the
compound (Table 4).
From Table 4, there are a higher number of compounds identi-
fied as carrier mediated efflux substrates compared to influx sub-
strates. The majority of compounds that were identified as effluxsubstrates are substrates of the P-gp transporter, which is always
tested due to the great influence this transporter has on reducing
absorption of many compounds.
We compared the permeability values obtained from Caco-2
and MDCK cell lines for all compounds and subgroups of com-
pounds showing specific routes of absorption as described in
Table 4. Two statistical methods were employed; 1) paired student
t-test to compare MDCK and Caco-2 permeability values of a sub-
group of compounds, and 2) comparison of the coefficients of the
correlation lines of subgroups of compounds, e.g. efflux substrates
and compounds with passive transcellular absorption. The results
for subgroups indicated that permeabilities through MDCK and
Caco-2 cell lines are correlated with similar slopes and intercepts
for compounds with different absorption mechanisms (Figs. S1eS7
and Table S2 in the Supporting Information III). The only significant
difference between the correlation lines was the difference be-
tween compounds undergoing transcellular and paracellular ab-
sorption routes (p value 0.0023). However, despite the different
tightness of the Caco-2 and MDCK cell lines, the observed differ-
ence may be due to the narrow range of permeability values of the
compounds with paracellular absorption route resulting in a non-
significant correlation between MDCK and Caco-2 solubility of
this subgroup (Fig. S1 in Supporting Information III). This hypoth-
esis is supported by the results of a paired student t test between
70/80%





































Fig. 2. Permeability thresholds determined by CART analysis with higher misclassifi-
cation costs applied to false positives for different HIA cut offs of 30%, 50%, 70%, 80%
and 90% on %HIA versus permeability plot including areas of outliers (A ¼ low
permeability, high oral absorption; B ¼ high permeability, low oral absorption).
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undergoing paracellular absorption (as a main or shared transport
route) showed no significant difference between Caco-2 and MDCK
permeabilities (p > 0.05). In addition paired t tests for all different
absorption mechanism groups and no significant differences be-
tween the two cell lines for these absorption groups were found.
Therefore, we can conclude that in general there are no statistically
significant differences between the two cell lines even when
considering separately the compounds with different absorption
mechanisms. Therefore, the data from both these cell lines can be
combined into a larger permeability dataset for use in further
modelling.
3.2. Determining permeability threshold for an effective oral
absorption
In this work we use the large dataset of combined Caco-2 and
MDCK permeability and a statistical method (CART) to identify
statistically valid permeability threshold for high/low oral absorp-
tion. Using CART analysis, a permeability threshold value was ob-
tained to predict the high or low intestinal absorption (HIA class)
using a training set of 356 compounds. Several different analyses
were performed where high absorption compounds were defined
as those having HIA values of above 30, 50, 70, 80 or 90%. In order to
optimise the threshold selection, various CART models using
different misclassification cost ratios for false positives: false neg-
atives (FP:FN) were generated [51,53]. The results below show the
permeability threshold selected by the CART analyses and the ac-
curacy, specificity and sensitivity of the class prediction (Table 5).
It can be seen in Table 5 that using high ratios of (FP:FN)
misclassification costs results in improved accuracy of the perme-
ability threshold for classification of compounds into high or low
absorption groups for all definitions of HIA class. For example using
equal misclassification costs to find permeability threshold for
dividing compounds into 30% or <30% HIA is not successful at all
(Model 1 Table 5) but increasing the cost of false positives to five
times that of the false negatives results in a high accuracy of clas-
sification and a robust threshold of5.98 (in log units) (model 6). It
must be noted here that different high/low definitions of HIA result
in different proportions of compounds in “high” or “low”Table 5
The permeability thresholds selected by CART and HIA class predictionwith equal and hig
than 30, 50, 70, 80 and 90%.






1 30% t 1:1 0.000
v 0.000
2 50% t 1:1 0.626
v 0.470
3 70% t 1:1 0.562
v 0.522
4 80% t 1:1 0.645
v 0.630
5 90% t 1:1 0.565
v 0.487
6 30% t 5:1 0.672
v 0.800
7 50% t 4:1 0.664
v 0.720
8 70% t 3:1 0.645
v 0.630
9 80% t 2.5:1 0.645
v 0.630
10 90% t 2:1 0.566
v 0.533
t: training set; v: validation set.
The most accurate classification for the validation set has been highlighted in bold.absorption classes, and hence the choice of misclassification cost
ratios to reflect the ratios of highly absorbed to poorly absorbed
compounds [51,53]. Therefore by applying higher misclassification
costs to reduce false positives, this has shifted the permeability
threshold in order to reduce the number of false positives due to
the under representation of the poorly absorbed class (Fig. 2). The
one exception to this is the 80% HIA class definition, where applying
misclassification costs had no effect on the permeability threshold.
In practice, when using the permeability threshold to classify high/
low absorption compounds, the suitable threshold suggested by
models 6e10 can be used for HIA class definition. The permeability
thresholds determined by CART when applying higher misclassi-
fication costs from Table 5 can be shown below (Fig. 2) when
plotting fraction absorbed against permeability for the training and









1.000 0.000 6.11 0.78
0.986 0.000
0.905 0.692 6.02 0.96
0.939 0.500
0.910 0.618 5.91 1.23
0.948 0.550
0.745 0.865 5.15 7.08
0.741 0.850
0.785 0.720 5.08 8.32
0.762 0.639
0.874 0.769 5.98 1.05
0.914 0.875
0.803 0.827 5.64 2.29
0.864 0.833
0.745 0.865 5.15 7.08
0.741 0.850
0.745 0.865 5.15 7.08
0.741 0.850
0.759 0.745 5.00 10.0
0.738 0.722
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absorbed and permeability. It is common in the literature to assume
a sigmoid fit to the relationship between HIA and permeability
[32,36,62]. However, there are too few points at the lower plateau
region to justify fitting a sigmoidal fit from statistical point of view;
in spite of this we found a r2 of 0.435 for a sigmoid fit to the whole
433 compounds. The collection of more data in the 0e50% region
may resolve this problem.
From Fig. 2, there are compounds that are highly absorbed but
have permeability values below the threshold and vice versa. The
most pronounced outliers have been shown in figure (Fig. 2) using
boxes A and B. Compounds with low permeability but high fraction
absorbed (Region A on Fig. 2) have been identified as mainly highly
soluble and substrates for influx carrier mediated transporters.
Examples of these are ribavirin and lamivudine [63,64]. Due to the
lower levels of these transporters, particularly PEPT1 in vitro, the
cell permeability underestimates the percentage absorbed of this
set of compounds. On the other hand, compounds with high
permeability but low fraction absorbed tend to be those that are
susceptible to gut metabolism and poorly soluble from this dataset
(Region B on Fig. 2). Examples of compounds in this outlier group
are lovastatin and tacrolimus [65,66].
Although the liver is the main metabolising organ, gut meta-
bolism can contribute significantly to overall metabolism and
should be considered [67]. Compounds susceptible to gut meta-
bolism, specifically CYP3A4 substrates, are highly permeable
in vitro but are poorly absorbed in vivo. However there are other
CYP3A4 substrates in this dataset which do not appear to undergo
extensive gut metabolism so are both highly absorbed and highly
permeable. Reasons for why some compounds are susceptible to
gut metabolism and others are not even though they are both
CYP3A4 substrates could be due to the different biotransformation
rate by this enzyme, solubility/dissolution rate, permeation rate,
dose amount and substrate affinity [67e69]. A list of theseTable 6
The results of CART analysis for the best permeability and solubility related trees using p









1 Molecular descriptorsa Molecular descriptorsa 3:1
2 Solubility (mg/ml) Solubility (mg/ml) 2:1
3 GSE solubility GSE solubility 2:1
4 MPbAP MPbAP 1:1
5 Solubility (mg/ml) GSE solubility 2:1
6 Dose number MPbAP 2:1
7 MPbAP GSE solubility 2:1
8 MPbAP Solubility (M) 2:1
9 Solubility (mg/ml) Solubility (M) 2:1
10 GSE solubility Solubility (M) 2:1
11 GSE solubility Molecular descriptorsa 2:1
12 MPbAP Molecular descriptorsa 2:1
FP: false positive; FN: false negative; GSE: General solubility equation; MPbAP: melting
a These are the molecular descriptors statistically selected by CART out of all the molecompounds in regions A and B in Fig. 2 can be found in the
Supporting Information II.
3.3. Oral absorption prediction using solubility, dose number and
melting point
From Fig. 2, we have identified potential outliers in the rela-
tionship between oral absorption and permeability. Using the
models built with permeability and solubility parameters and
molecular descriptors, these misclassifications could be classified
correctly due to the influence of solubility and other related pa-
rameters on oral absorption. For example, false positives are highly
permeable compounds with poor oral absorption. These com-
pounds maybe poorly soluble compounds or those undergoing gut
metabolism.
CART classification models to predict highly absorbed or poorly
absorbed class of compounds (HIA  80 or <80%) were built using
the training sets described in thematerial andmethods section. The
permeability for 80% absorption (at 5.15 log scale according to
Table 5) was used to develop the models. The 80% class definition
was chosen as when using lower HIA% values to define high or low
absorption led to very low number of poorly absorbed compounds,
compared with highly absorbed compounds which would seriously
reduce significance of models. The HIA 90% cut-off for class defi-
nition, although used in some previous work, was not chosen in this
work as (based on our preliminary analysis) that definition resulted
in poor overall accuracy in the produced models, and the 90%
threshold is too high to predict oral absorption class effectively.
Selected CART models produced for the prediction of HIA class
(HIA > or 80%) using permeability and solubility related param-
eters and molecular descriptors are shown in Table 6. Note that for
all models permeability was always used as the first split variable
and the table gives the variables used for the second splits. After the
second splits, CART picks the most significant parameter out of allermeability threshold for 80% or <80% HIA as the first split.









6:1 t 356 0.72 0.754 0.955
v 77 0.519 0.593 0.875
10:1 t 241 0.723 0.823 0.879
v 54 0.618 0.674 0.917
1:1 t 261 0.695 0.891 0.779
v 53 0.638 0.829 0.769
1:1 t 249 0.753 0.876 0.859
v 48 0.631 0.757 0.833
10:1 t 200 0.754 0.820 0.920
v 40 0.583 0.667 0.875
10:1 t 196 0.758 0.791 0.958
v 40 0.636 0.636 1.000
1:1 t 256 0.723 0.884 0.818
v 51 0.667 0.800 0.833
1:1 t 197 0.776 0.866 0.896
v 40 0.697 0.697 1.000
10:1 t 241 0.754 0.766 0.985
v 54 0.533 0.581 0.917
1:1 t 201 0.722 0.881 0.820
v 40 0.663 0.758 0.875
1:1 t 262 0.717 0.887 0.809
v 53 0.650 0.780 0.833
1:1 t 257 0.746 0.880 0.848
v 51 0.688 0.750 0.917
point based absorption potential.
cular descriptors and solubility parameters.
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able. In Table 6, in model 1 after permeability as the first split
variable, CART automatically builds the rest of the tree by selecting
the most significant property/molecular descriptor. For models
2e4, solubility; calculated solubility (GSE method or melting point
based absorption potential (MPbAP)) were used on both (high and
low permeability) sides of the tree for the second split, and after
this CARTautomatically built the rest of the tree. Models 5e10 were
built using different combinations of solubility and related pa-
rameters on either the high or low permeability side of the trees.
Finally, models 11e12 were combinations of the molecular de-
scriptors and solubility related parameters in high or low perme-
ability sides of the trees.
From Table 6 it is interesting to note which properties were used
to build the selected models. Note that many combinations of
melting point, dose and solubility related parameters were tested
and Table 6 is a selection of the best models based on accuracy
(SE  SP). Using melting point did not yield high prediction models
(data not shown). It was thought that due to the relationship be-
tweenmelting point and solubility this parametermight be a useful
alternative to solubility, as these two properties share similar
functions such as enthalpy energies which must be overcome in
order to solubilise or melt. Additionally, dose number was useful
only for splitting the high permeability compounds and the com-
binationwith MPbAP yielded for a good prediction model (Model 6
in Table 6). Dose number is used to define high and low solubility
for the BCS system [4,42]. By definition, increasing the dose or a low
solubility will result in a high dose number and this is expected to
lead to poor oral absorption of highly permeable compounds.
The majority of the selected models in Table 6 incorporate sol-
ubility and predicted solubility especially for highly permeable
compounds. Unlike GSE solubility which was used on both sides of
the CART trees, MPbAP only yielded good models when used for
splitting on the high permeability compounds. Experimental sol-
ubility in two units, mg/ml or molar, have been used in models.
Solubility in M, which takes into account the molecular weight and
is smaller for high molecular weight compounds, was utilised for
splitting of the low permeability compounds (Models 8, 9 and 10).
In terms of the role of solubility in the absorption process, one
would expect poor absorption of poorly soluble compounds, due to
solubility being the rate limiting factor in absorption. However, this
is not the picture presented by the classification trees 1e12 (See
Supporting Information III). According to the classification tree
models, the low permeability and high solubility compounds al-
ways have low intestinal absorption (<80%). This is probably due to
the highly polar nature of such compounds. On the other hand,
poorly water soluble compounds of low permeabilitymay be highly
absorbed from the small intestine if they have small polar surface
area (models 3e7) or a small sum of absolute atomic partial charge,
ABSQ (models 2, 8, 9, 10), which also indicates polarity of mole-
cules. The absorption limiting effect of poor aqueous solubility is
not seen for highly permeable compounds either. Here, highly
permeable compounds with poor aqueous solubility are still highly
absorbable from GI, with the exception of compounds with high
polar surface area, low dipole moment (models 2, 5, 9) or small
Balaban Topological index which is an indicator of molecular shape
(models 3, 4, 10, 11). The reason for not observing the limiting effect
of poor aqueous solubility here could be firstly the lack of enough
representation of these solubility limiting compounds in the
dataset and secondly the effect of formulation of oral dosage forms
with measures taken for improved dissolution rate (excipients,
particles size, etc) which could mask previous solubility limiting
effects of such compounds.
The top molecular descriptors used in models 1e12 in Table 6
are polar surface area (PSA) and Balaban topological index. Bothof these descriptors are related to both absorption and solubility
prediction models [70,71]. PSA is the area of the van der Waals
surface that arises from oxygen and nitrogen atoms or hydrogen
atoms bound to these atoms [70]. The Balaban topological index, J,
is the average-distance sum connectivity and relates to the shape of
the molecule [72]. The next popular descriptors are sum of absolute
charges on each atom of the molecule (ABSQ) and lowest unoccu-
pied molecular orbital energy (LUMO) calculated by VAMP [73].
3.4. Selected CART models
In order to generally compare models 1e12 from Table 6, the
compound datasets used to build the resulting models should be
taken into account. The degree of difficulty of the classification
model will change depending on the compounds in the dataset.
When the dataset is large, e.g. in the case of model 1, there are more
compounds that maybe harder to classify in the dataset. The model
with the highest SP  SE for the validation set is model 8, with a
value of 0.697; however this is based on a training set of only 197
and a validation set of 40 compounds due to the missing experi-
mental solubility or melting point values. On the other hand, model
12 has a slightly lower SP  SE of 0.682 for the validation set, but it
was built using a training set of 257 and assessed using a validation
set of 51 compounds; therefore it may be more suitable for
generalization ability for new compounds, as it covers a wider
chemical space compared with model 8. Moreover the only
experimental parameter used in this model is melting point that is
used for the calculation of MPbAP. We also selected model 7, which
has used calculated solubility and MPbAP, and model 3 which has
used only the calculated solubility to indicate the roles of solubility
and absorption potential. The CART models are presented in
Figs. 3e5. Brief description of molecular descriptors has been pre-
sented in Supporting Information III (Table S3).
In Fig. 3, Model 3, permeability is used as the first CART split
variable and then calculated solubility from GSE equation on both
sides of the tree was used as the second split variable. Polar surface
area and Balaban index were picked automatically by the CART
analysis. The model shows that highly permeable and highly sol-
uble compounds have high intestinal absorption (node 7). More-
over, compounds with low predicted solubility (4.74) can still be
classed as highly absorbed if the Balaban index is>1.57. Compounds
with a low Balaban index will be poorly absorbed and such ex-
amples include mebendazole and ketoconazole. In spite of this
there are misclassifications in this node 8 in Fig. 3; ziprasidone and
tiagabine are misclassified as poorly absorbed when in fact they
have HIA 80%. Balaban topological index, J, a highly discriminant
topological descriptor, gives an indication of shape including
branching and cyclicity of a molecule. A high index can indicate a
high number of branches, close proximity of the position of these
branches, as well as increased number of double bonds on a
molecule. A low index can indicate a low level of branching as well
as a larger number of cyclic groups [72]. The relationship between
Balaban index and solubility with reference to melting point has
been shown previously in the literature [15]. In spite of this there is
not much difference between the calculated GSE solubilities be-
tween the two nodes although there is a significant difference
between the average melting points (222 C compared with 193 C
in nodes 8 and 9 respectively), suggesting a possible effect of
melting point on absorption.
Poorly permeable compounds are highly absorbed only for
compounds with predicted solubility 1.12 if the PSA is low. This
is a higher solubility value than the threshold seen in splitting of
node 3, and is not expected to limit the intestinal absorption. There
are somemisclassified compounds in this group, which are actually
poorly absorbed despite having a low PSA, therefore classified as
Tree graph for 80.000000

























<= -5.150000 > -5.150000
GSE solubility
<= -1.120000 > -1.120000
ACD_PSA
<= 89.240000 > 89.240000
GSE solubility
<= -4.740000 > -4.740000
Balaban Topological index
<= 1.569850 > 1.569850
LOW     
HIGH
Fig. 3. Model 3 CART permeability and predicted solubility (GSE) model when higher misclassification costs of two to reduce false positives were applied to low GSE solubility node.
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<= -5.150000 > -5.150000
GSE solubility
<= -1.120000 > -1.120000
ACD_PSA
<= 89.240000 > 89.240000
MPbAP
<= 2.160000 > 2.160000
Balaban Topological index
<= 1.539019 > 1.539019
LOW     
HIGH
Fig. 4. Model 7 CART permeability, predicted solubility (GSE) and MPbAP model when higher misclassification costs of two to reduce false positives were applied to GSE node.
D. Newby et al. / European Journal of Medicinal Chemistry 90 (2015) 751e765760highly-absorbed according to this tree. The reasons for mis-
classifications is mostly due to efflux mechanisms reducing the
absorption of compounds and examples include nadolol and nor-
floxacin which both have low PSA and classed as highly absorbed
but are observed to have poor oral absorption due to transporter
effects [31,74]. Unlike nadolol which is classed as highly soluble,
norfloxacin is considered as a poorly soluble compound in class IVof the BCS system. One may speculate that presence of more such
compounds in this dataset, may have led to further split of this
node based on solubility to class compounds with extremely low
aqueous solubility as poorly soluble.
Model 7 was built using GSE solubility for the second split of the
poorly permeable compounds (node 2) and MPbAP for the second
split of highly permeable compounds in node 3. This model was
Tree graph for 80.000000

































<= -5.150000 > -5.150000
SHHBd
<= 6.612200 > 6.612200
VAMP HOMO
<= -8.757106 > -8.757106
SsCH3
<= 3.509010 > 3.509010
LogP
<= 1.239340 > 1.239340
MPbAP
<= 2.160000 > 2.160000
Balaban Topological index
<= 1.539019 > 1.539019
LOW     
HIGH
Fig. 5. Model 12 CART permeability and MPbAP model when higher misclassification costs of two to reduce false positives were applied to permeability node.
Table 7
Examples of permeability thresholds determined by the literature.
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a MDCKII strain (MDCK-LE) cell line with isolated low endogenous efflux trans-
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validation set. The descriptors used in this tree are the same as in
Fig. 3. Model 3, however, using the split based onMPbAP appears to
split more compounds into node 6 to be classed by Balaban topo-
logical index. In this tree a lower threshold of 1.54 for Balaban To-
pological index increases the number of correctly classified poorly
absorbed compounds when permeability is high examples of this
type of compounds include the BCS class II compounds spi-
ronolactone and ketoconazole.
From Fig. 5 classification of highly permeable compounds in
node 3 is the same as Fig. 4. Poorly permeable compounds with a
high number of hydrogen bonding donors (SHHBd > 6.61) will be
poorly absorbed, which is confirmed by the literature such as Lip-
inski's rule of five, where compounds are likely to be poorly
absorbed if two or more of the following rules are broken: more
than >5 hydrogen bond donors, >10 hydrogen bond acceptors, log
P > 5 and molecular weight > 500 Da [75]. Compounds can be
misclassified as poorly absorbed based on a higher number of
hydrogen bond donor groups mainly due to being highly absorbed
due to substrate specificity for influx transporters. Examples of
misclassified compounds include ribavirin and folinic acid.
A poorly permeable compound will still be highly absorbed if
HOMO energy is greater than8.76. A comparison of the molecular
structures in this node indicates that these compounds have more
aromatic rings compared with compounds with lower HOMO en-
ergy (node ID 8) where the average number of aromatic rings is one.
In addition it was also found that a number of low HOMO com-
pounds had a permanent quaternary ammonium or ionisable
centre such as trospium and neostigmine.
Even if a poorly permeable compound has a lowHOMO energy it
can still be classed as highly absorbed if the compound has few
methyl groups (SsCH3  3.509) or log P > 1.239. Compounds with
log P < 1.24 are classified as poorly absorbed, but there are falsenegatives such as orally administered cephradine and baclofen,
which are both highly absorbed but are predicted as poorly
absorbed by having a low log P. The reason for some of the false
negatives in this node is that some of these compounds are sub-
strates for influx carrier mediated systems.3.5. Discussion of related literature
3.5.1. Subjective definition of a permeability threshold for oral
absorption prediction
Permeability from in vitro cell based assays has been utilised
frequently in the literature. These thresholds are then used to give
an indication of potential oral absorption from permeability data. Aporter expression.
D. Newby et al. / European Journal of Medicinal Chemistry 90 (2015) 751e765762summary of a few permeability thresholds defined by other works
is shown in Table 7.
Early permeability thresholds defined by works in the literature
are based on small compound datasets. Artursson et al. [37] set a
permeability threshold of >1  106 cm/s for complete absorption
based on 20 compounds. Based on other works in the literature this
value is too low to predict complete absorption, where other works
have permeability thresholds one order of magnitude higher. For
example, from Table 7, Yee et al. [41] has stated > 10  106 cm/s
permeability is related to absorption > 70%. What is apparent is the
difference between permeability thresholds from different sources,
which is dependent on the small number of compounds tested and
inter and intra laboratory differences [13]. In comparison, our
permeability thresholds are statistically defined by CART rather
than a subjective determination; the thresholds picked by CART are
similar to those in the literature, especially when high absorption
was set at either as >70%, >80% or >90%, indicating that high ab-
sorption is related to permeability >7  106 cm/s. The perme-
ability threshold determined by Hou et al. [13] of 6  106 cm/s is
based on data from numerous sources and is very similar to our
70e90% class permeability thresholds.
Di et al. (2011) [40] used MDCK II cells with low efflux endog-
enous transporter expression (MDCK-LE) to define a threshold of
3  106 cm/s to distinguish between low/medium absorbed
compounds (<80% HIA) and highly absorbed compounds. A dataset
published by Varma et al. (2012) [36] using the MDCK-LE cell line
shows that the permeability threshold defined ROC analysis using
this cell line (5.0  106 cm/s) is similar to Caco-2 thresholds in
the literature, and this value is in agreement with CART perme-
ability thresholds in this work. The threshold similarity between
Caco-2 and MDCK cell lines is expected by the linear relationship
between these two cell lines shown in this work.
Finally more recently Pham-The et al. (2013) [62] established a
rank order relationship between Caco-2 permeability and oral ab-
sorption for 324 compounds. The thresholds definedwere based on
standard compounds from the FDA with known fraction absorbed
values. For example, for a compound to be considered highly
absorbed, it must have an apparent permeability greater than
metoprolol, a FDA standard compoundwith knownHIA. In this case
Caco-2 permeability greater than 16 106 cm/s, which is 0.8 times
the metoprolol permeability was used to take into account the
lower HIA threshold of 85% used. For the low absorption threshold
an average value of 0.7  106 cm/s, based on the permeability of
mannitol was used. In this study this threshold was to define
compoundswith HIA <30% however mannitol has a reported HIA of
~18% therefore the use of this permeability threshold may increase
the number of false negatives.
3.5.2. The influence of permeability and solubility on oral
absorption modelling
Permeability and solubility are two important factors important
for oral absorption. Therefore the effect these two properties have
on oral absorption and in turn how they influence oral absorption
prediction is important to establish. From the literature there is a
lot of focus on permeability and as shown in this work there is a
rank order relationship between HIA and permeability. On the
other hand, solubility seems not to be regarded as important as
permeability in relation to oral absorption, but as a factor that can
lead to poor (solubility limited) absorption in addition to other
limiting factors such as transporter and enzyme effects. Further-
more, the relative importance of solubility could be dependent on
the research organization and the mechanistic importance of sol-
ubility in regards to oral absorption may not be considered [6]. In
spite of this the main reasons for poor oral absorption have been
shown to be either poor permeability or poor solubility or both[76].
The results of this work indicate that permeability is the most
important parameter influencing oral absorption prediction.
Permeability was always picked as top molecular descriptor when
building CART models. In contrast, solubility and the related pa-
rameters were never picked as the top descriptor or even in the
second split, unless selected manually at this second level in order
to examine if there was any influence of solubility on oral absorp-
tion prediction.
It is apparent that solubility can be a rate-limiting step in oral
absorption [4,12,77]. This is based on the principle that a drug must
be dissolved in the gastrointestinal fluid in order to then permeate
the membrane to be absorbed. However formulation development
strategies can overcome this problem, for example by employing
solubilising agents, pH control, or complexation [78].
In any case, the results obtained here do not directly indicate the
poor absorption of poorly soluble compounds and the effects of
poor solubility in limiting absorption. According to this study, in
general compounds that are highly permeable but have low solu-
bility can be predicted as highly or poorly absorbed depending on
the other molecular properties. Moreover, poorly permeable but
highly soluble compounds are classed as poorly absorbed, although
there are exceptions to this i.e. the false negatives. One important
consideration in analysing these results is the threshold of solubi-
lity in the models. For example, poorly permeable compounds with
poor solubility may have high oral absorption (see models 3 and 7
for example). However, it must be noted here that poor solubility
has been defined as <1.12 in log unit, which is quite high when
comparing with the threshold values suggested in the literature for
BCS classes II and IV [4]. A further observation from the models
could be the poor representation of very poorly soluble compounds
in the dataset i.e. those having solubility-limited absorption. As a
result, it may not be statistically advantageous to further split the
classification tree to allocate these compounds into a separate
terminal node. For example in a large dataset of fraction absorbed,
24were highlighted to have solubility issues out of 648 compounds
[13]. Besides this the formulation techniques may improve the
dissolution rate of these compounds and overcome the low solu-
bility issues of compounds in the fraction absorbed dataset used in
this work.
It is difficult to directly compare other models in the literature
with this work, as different data sets and methods have been used.
Early oral absorption models which use a diverse dataset are too
small to represent all the different biological processes of absorp-
tion and other factors such as solubility. The majority of oral ab-
sorption models in the literature do not include compounds which
have solubility issues [10,79]. Therefore, these and other models
may only be useful for predicting absorption for compounds with
no solubility issues. In addition, some of these studies also removed
compounds with transporter effects or compounds with a perma-
nent charge [13,80]. This simplifies the resulting models by
removing those compounds with these rate-limiting steps. How-
ever, the main issue with this is the potential impact on the
generalizability of the resulting models which will fail to predict
the oral absorption of these excluded compound classes despite the
increased need in current drug discovery projects for prediction of
absorption of the increasingly poorly-soluble compounds.
In studies by Zhao and co-workers, datawith solubility and dose
dependency was defined and not used in the majority of the initial
models. However upon inclusion of these compounds with solu-
bility issues the resulting models had higher error [81]. It was also
noted however that the more insoluble a compound the lower the
resulting absorption. In a later study compounds identified with no
solubility issues were used to built models and some of these
resulting models were then used to predict absorption for the
D. Newby et al. / European Journal of Medicinal Chemistry 90 (2015) 751e765 763compounds with dose-limiting and dose dependency effects.
Overall prediction of absorption of these excluded compounds was
in agreement with observed values or the models tended to over-
estimate absorption [12]. Our oral absorption models are able to
predict oral absorption class even with poor solubility for majority
of compounds by incorporating molecular descriptors in addition
to permeability and solubility into the models. From the list of 27
compounds with solubility and related problems defined by Zhao
et al. (2001) [12], 14 were utilised in this work with experimental
permeability and solubility values present. Using the best models
chosen, 11 out of 14 compounds were predicted correctly by model
3, 12 out of 14 correct predictions bymodel 7 and all 14 compounds
were predicted correctly using model 12.
With the extended use of BCS classification in drug discovery,
the influence of solubility and permeability is of great interest [82].
In work by Pham-The et al. (2013), oral absorption was predicted,
taking into account solubility, which is a general aim of the BCS. In
this study, Pham-The, using a rank order relationship, noted that
the relationship between permeability and oral absorption is less
certain for poorly absorbed compounds which is a similar obser-
vation to our results. They also found various contour plots that
incorporating solubility improves classification of HIA based on
permeability data by about 10%; therefore showing that potentially
using solubility in models is advantageous for oral absorption
prediction.
From the literature examples as well as this work the influence
of solubility could be included to help predict oral absorption.
However the main issue is the lack of experimental solubility for
drug compounds to be used in oral absorption modelling. The use
of experimental solubility data in the prediction of oral absorption
alongside permeability yields good accuracy to predict oral ab-
sorption however the lack of experimental solubility limits the
application for the prediction of new compounds. Therefore, ac-
cording to our results, predicted solubility such as GSE solubility
and parameters such as MPbAP can be used successfully instead of
experimental solubility. These are based on simple properties of
lipophilicity, melting point and dose. Despite this, melting point
alone was not successful in providing an adequate alternative to
experimental solubility, even though partition coefficient was also
available to be used concurrently in the same model. Due to the
complexity of solubility it is difficult to find one molecular
descriptor to adequately describe all the solubility processes.
4. Conclusion
The two main properties influencing oral absorption are
permeability and solubility. In order to establish the relationship of
these two properties with oral absorption classification, firstly, a
larger dataset was established from different sources. This was
made possible through combining Caco-2 and MDCK permeability
after comparing a linear relationship between these two cell lines,
even for compounds with different absorption mechanisms.
Secondly, using the combined permeability dataset, a perme-
ability threshold for various levels of oral absorption was investi-
gated using CART analysis. Due to the larger number of highly
absorbed compounds, misclassification costs were applied and
improved the threshold definition statistically. The thresholds ob-
tained from the objective CARTanalysis are similar to some of those
in the literature using mainly subjective methods to determine
permeability thresholds.
Finally the permeability thresholds were then used to build
decision trees with the CART method, incorporating solubility and
related parameters, as well as the calculated molecular descriptors
to predict oral absorption class. Melting point is not a useful
parameter to predict absorption when used stand-alone. However,when melting point is utilised to calculate combined parameters
such as predicted (GSE) solubility and melting point-based ab-
sorption potential, it yielded high accuracy models compared with
experimental solubility. This is due to the possibility of using more
data for the training of the models when calculated or more easily
accessible experimental parameters are used. Therefore, models
built using predicted values of solubility and melting point-based
absorption gave rise to better predictive models. Molecular de-
scriptors utilised in the models, such as those describing size,
shape, polarizability and hydrogen bonding, can be related to both
permeability and solubility and therefore oral absorption. These
molecular descriptors were shown to be necessary for oral ab-
sorption models to correctly classify the compounds with
solubility-limited absorption. The models built in this work are
useful for a better mechanistic understanding of the effect of these
properties and how they contribute to overall oral absorption.
Appendix A. Supplementary data
Supporting information I contains the dataset of 932 com-
pounds with HIA%, Caco-2 permeability, MDCK permeability,
aqueous solubility, melting point and the references. Supporting
information II contains compound lists and information regarding
the outliers in Figs. 1 and 3 including references. Supporting
Information III contains a table comparing the differences in
transporter and enzyme expression between the human small in-
testine, Caco-2 and MDCK cell lines, the significance testing and
graphs for the different absorption mechanisms when comparing
Caco-2 and MDCK cell lines, all the models (CART decision trees)
produced from this work, and finally a list of molecular descriptor
utilised in the 12 models presented in this work. Supplementary
data related to this article can be found at http://dx.doi.org/10.1016/
j.ejmech.2014.12.006.
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